{"id":960498,"date":"2026-05-08T09:18:18","date_gmt":"2026-05-08T13:18:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/envue-medical-adds-to-intellectual-property-portfolio-by-securing-uspto-notice-of-allowance-for-ultrasound-enhanced-cannabinoid-drug-delivery-technology\/"},"modified":"2026-05-08T09:18:18","modified_gmt":"2026-05-08T13:18:18","slug":"envue-medical-adds-to-intellectual-property-portfolio-by-securing-uspto-notice-of-allowance-for-ultrasound-enhanced-cannabinoid-drug-delivery-technology","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/envue-medical-adds-to-intellectual-property-portfolio-by-securing-uspto-notice-of-allowance-for-ultrasound-enhanced-cannabinoid-drug-delivery-technology\/","title":{"rendered":"ENvue Medical Adds to Intellectual Property Portfolio by Securing USPTO Notice of Allowance for Ultrasound-Enhanced Cannabinoid Drug Delivery Technology"},"content":{"rendered":"

\nPatent Expands Company’s Proprietary Surface Acoustic Wave Platform into Advanced Therapeutic Delivery Applications
\n<\/h2>\n
\n

TYLER, Texas, May 08, 2026 (GLOBE NEWSWIRE) — ENvue Medical, Inc.<\/a> (NASDAQ: FEED) (“ENvue,” “ENvue Medical” or the “Company”), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17\/025,969, covering a novel drug delivery system utilizing the Company’s proprietary surface acoustic wave (SAW) technology to enhance transdermal delivery of cannabinoid-based therapeutics.<\/p>\n

The allowed claims provide broad intellectual property protection across multiple components of the combined SAW ultrasound and cannabinoid transdermal delivery system, including transdermal patch configurations, portable SAW-generating platforms, and methods shown to produce synergistic enhancement in cannabinoid absorption through the skin compared to administration via the transdermal patch alone.<\/p>\n

Cannabinoid-based therapeutics continue to attract growing scientific, pharmaceutical, and commercial interest globally, particularly in pain management, neurology, inflammation, and chronic disease applications. ENvue Medical believes its ultrasound-based delivery platform may provide future opportunities to improve therapeutic administration and enable strategic collaborations across multiple treatment categories.<\/p>\n

“This Notice of Allowance validates a meaningful expansion of our SAW platform into an entirely new therapeutic category,\u201d said Doron Besser, MD, Chief Executive Officer of ENvue Medical. \u201cWe believe that the USPTO’s recognition of the synergistic effect between our ultrasound technology and cannabinoid transdermal delivery, and its determination that this combination was non-obvious, reflects the depth and breadth of our intellectual property portfolio. We believe this positions ENvue favorably as interest in cannabinoid-based therapeutics continues to grow, and we look forward to exploring the strategic opportunities this patent creates for the Company.”<\/p>\n

The Company believes this patent allowance further reinforces the value and versatility of its proprietary SAW technology platform and highlights the potential for future applications beyond its currently marketed products.<\/p>\n

\n About ENvue Medical, Inc.<\/strong>
\n
ENvue Medical, Inc. (NASDAQ: FEED) is a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings. Headquartered in Tyler, Texas, with research and development in Tel-Aviv and Nesher, Israel, the Company focuses on two distinct technology platforms:<\/p>\n